Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial

Homeopathy ◽  
2012 ◽  
Vol 101 (04) ◽  
pp. 217-223 ◽  
Author(s):  
A.K. Hati ◽  
B. Paital ◽  
K.N. Naik ◽  
A.K. Mishra ◽  
G.B.N. Chainy ◽  
...  
Keyword(s):  
Specific Antigen ◽  
Urine Volume ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Intermittent Flow ◽  
Urinary Flow ◽  
Residual Urine Volume ◽  
Homeopathic Treatment ◽  
Presenting Symptoms ◽  
Residual Urine

Background: Benign Prostatic Hypertrophy (BPH) is common in older men. This study compared homeopathic treatment strategies using constitutional medicines (CM) or organopathic medicines (OM) alone or in combination (BCOM) in patients suffering from BPH.Methods: 220 men aged 30–90 years were recruited in Odisha, India. Patients presenting symptoms of prostatism, with or without evidence of bladder outflow obstruction were included in the study. Patients with serum prostate specific antigen (PSA)> 4 nmol/mL, malignancy, complete urine retention, stone formation and gross bilateral hydronephrosis were excluded. Patients were sequentially allocated to OM, CM or BCOM. The main outcome measure was the International Prostate Symptom Score (IPSS).Results: 73, 70 and 77 patients respectively were sequentially allocated to OM, CM or BCOM. 180 patients (60 per group) completed treatment and were included in the final analysis. Overall 85% of patients showed improvement of subjective symptoms such as frequency, urgency, hesitancy, intermittent flow, unsatisfactory urination, feeble stream, diminution of residual urine volume but there was no reduction in prostate size. Treatment response was highest with BCOM (38.24%) compared to OM (31.62%) and CM (30.15%). Effect sizes were highest for the decrease in IPSS, residual urine volume and urinary flow rate.

scholarly journals COMPARATIVE EFFICACY OF INTERMITTENT AND DAILY DOXAZOSIN THERAPY FOR LUTS ASSOCIATED WITH BPH

2011 ◽  
Vol 18 (1) ◽  
Author(s):  
Heru Nurdianto ◽  
Sabilal Alif ◽  
Tarmono Tarmono
Keyword(s):  
International Prostate Symptom Score ◽  
Urine Volume ◽  
Intermittent Therapy ◽  
Urinary Flow ◽  
Comparative Efficacy ◽  
Residual Urine Volume ◽  
Treatment Groups ◽  
Therapy Efficacy ◽  
Residual Urine ◽  
Group I

Objective: To investigate the efficacy of intermittent doxazosin therapy on LUTS associated BPH. Material  & Method: This study was performed between January to April 2010 enrolling 20 patients with LUTS associated BPH. Study subjects were randomly allocated to 2 therapeutic groups. The first group was assigned daily doxazosin therapy (11 patients), while the second group was assigned intermittent doxazosin therapy (9 patients). Initially all subjects were given doxazosin 2 mg daily for 2 weeks. Subsequently group I received doxazosin 2 mg daily therapy, while group II received doxazosin 2 mg every other day. All medications were taken up to 12 weeks. Outcomes were evaluated prior to therapy, and after 2, 4, 8, and 12 weeks of therapy. Efficacy of doxazosin therapy was measured by International Prostate Symptom Score (IPSS), peak urinary flow rate (Q max), and residual urine volume. Statistical analysis was performed to evaluate difference in efficacy between the treatment groups. Results: Daily doxazosin therapy for 2 weeks resulted in significant improvement of Q max and IPSS. After 4, 8, and 12 weeks significant improvement was maintained in both daily and intermittent groups, as measured by Q max, residual urine volume and IPSS. There were no significant differences in Q max, residual urine volume, and IPSS between the daily and intermittent groups at 4, 8, and 12 groups. Conclusion: There were significant improvements of Q max, residual urine and IPSS at 2 to 12 weeks in daily as well as intermittent doxazosin therapy groups. There were no significant differences in efficacy between daily and intermittent therapy groups

scholarly journals Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up

2013 ◽  
Vol 85 (2) ◽  
pp. 86 ◽  
Author(s):  
Roberto Giulianelli ◽  
Luca Albanesi ◽  
Francesco Attisani ◽  
Barbara Cristina Gentile ◽  
Giorgio Vincenti ◽  
...  
Keyword(s):  
Hospital Stay ◽  
Transurethral Resection ◽  
Randomized Study ◽  
Transrectal Ultrasound ◽  
Urine Volume ◽  
Isotonic Saline ◽  
Urinary Flow ◽  
Residual Urine Volume ◽  
Residual Urine

Objective: Transurethral resection of the prostate (TURP) is the current optimal thera- py for the relief of bladder outflow obstruction, with subjective and objective success rate of 85 to 90%. Aim of this study was to evaluate efficacy and safety of Plasmakinetic ener- gy (Gyrus electro surgical system), which produces vaporization of tissue immersed in isotonic saline against standard monopolar transurethral resection of the prostate. Methods: From January 2002 to April 2002, 160 consecutive patients, who had low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) were enrolled in this study. Patients were randomised to undergo bipolar TURP (80 patients) or monopolar TURP (80 patients). Preoperative work-up was assessed by administering IPSS, IIEF-5 and Qol questionnaires. All patients were submitted to uroflowmetry, transrectal ultrasound (TRUS), post-voidal residual urine measurement and PSA determination. In the two groups, IPSS, IIEF-5 and Qol, uroflowme- try, TRUS, post-voidal residual urine measurement, PSA determination and number of reopera- tions were evaluated at 1, 3, 6, 12, 18, 24, 30 and 36 months follow up, and then every year. Furthermore, in both groups operative time, resected tissue weight and perioperative complica- tions were analysed. Total postoperative catheter time, total post-operative hospital stay, haemo- globin loss were also recorded in the two groups. Results: Comparative data on IPSS symptom score, IIEF-5, Qol, PSA, peak urinary flow rate and post-void residual urine volume were similar in the two groups but showed a significant improve- ment respect to baseline values. The postoperative haemoglobin levels, postoperative catheteri- zation time, hospital stay and 3-year overall surgical re-treatment-free rate were significantly better in the bipolar group. Conclusions: Bipolar TURP has a comparable outcome to standard monopolar TURP at short and medium term regard to subjective and objective outcome measurements. Its impact on blad- der outlet function is also similar to that of monopolar TURP. Improvement in IPSS, Qol index, IIEF-5, Qmax and post-void residual urine volume were comparable in both group denoting sim- ilar efficacy of the techniques.

scholarly journals Safety and efficacy of prostatic artery embolization for large benign prostatic hyperplasia in elderly patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098628
Author(s):  
Chen Xu ◽  
Gang Zhang ◽  
Jin-jin Wang ◽  
Chun-xian Zhou ◽  
Min-jun Jiang
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Elderly Patients ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Antigen Level ◽  
Residual Urine Volume ◽  
Safety And Efficacy ◽  
Total Prostate Specific Antigen

Objective To assess the safety and efficacy of prostatic arterial embolization (PAE) for elderly patients with lower urinary tract symptoms secondary to large benign prostatic hyperplasia. Methods Twenty-eight patients (>80 years of age) with prostate volume >80 mL were enrolled from October 2016 to October 2019. PAE was performed using microspheres and functional results were evaluated at 1, 3, 6, and 12 months postoperatively. The following data were recorded: International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urine flow rate (Qmax), post-void residual urine volume, prostate volume and total prostate-specific antigen level. Results Selective prostatic arterial catheterization and embolization were achieved in 27 of 28 patients. Follow-up data were available for those 27 patients until 12 months postoperatively. Significant improvements were found at all postoperative time points in terms of the mean IPSS, mean QoL score, mean Qmax, mean post-void residual urine volume, mean total prostate-specific antigen level, and mean prostate volume. The overall complication rate was 46.4%. Conclusions PAE is an efficacious and safe treatment for elderly patients with large prostate volume; it may offer an effective approach for patients who are not candidates for open or endoscopic surgical procedures because of comorbidities.

Causes and Treatment of Residual Urine Volume after Orthotopic Bladder Replacement in Women

2000 ◽  
Vol 38 (6) ◽  
pp. 748-752 ◽  
Author(s):  
L. Jarolím ◽  
M. Babjuk ◽  
S.M. Pecher ◽  
M. Grim ◽  
O. Naňka ◽  
...  
Keyword(s):  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Bladder Replacement

scholarly journals The reliability and reproducibility of ultrasonography for measuring the residual urine volume in men with lower urinary tract symptoms

2014 ◽  
Vol 12 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Hassan A. Abdelwahab ◽  
Housseini M. Abdalla ◽  
Mahmoud H. Sherief ◽  
Mohamed B. Ibrahim ◽  
Mostafa A. Shamaa
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

POST-VOID RESIDUAL URINE VOLUME IN WOMEN WITH OVERACTIVE BLADDER SYMPTOMS

2004 ◽  
Vol 172 (5) ◽  
pp. 1911-1914 ◽  
Author(s):  
MARK MILLEMAN ◽  
PETER LANGENSTROER ◽  
MICHAEL L. GURALNICK
Keyword(s):  
Overactive Bladder ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Overactive Bladder Symptoms ◽  
Bladder Symptoms

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

1989 ◽  
Vol 4 (2) ◽  
pp. 87-94 ◽  
Author(s):  
J. Morote Robles ◽  
A. Ruibal Morell ◽  
J.A. De Torres Mateos ◽  
A. Soler Roselló
Keyword(s):  
Acid Phosphatase ◽  
False Positive ◽  
Normal Limit ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Prostatic Hypertrophy ◽  
Prostatic Specific Antigen ◽  
Positive Results

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Sign in / Sign up

Export Citation Format

Share Document